Minimising Toxicity and Maximising Response: T-Cell Engagers for Elderly Patients with Multiple Myeloma
The management of multiple myeloma (MM) in the elderly is challenging, exacerbated by age-related frailty and comorbidities. T-cell engagers (TCE) have been transformative to the treatment of relapsed MM, achieving deep and durable responses. This review evaluates the efficacy, toxicity, and other p...
Saved in:
| Main Authors: | Anthony McLoughlin, Matthew J. Rees |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Lymphatics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2813-3307/3/2/14 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
by: Andrée-Anne Pelland, et al.
Published: (2025-04-01) -
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01) -
Injection site reaction to teclistamab in a patient with multiple myeloma
by: Isabel C. Yoon, BS, et al.
Published: (2025-02-01) -
Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
by: Fahad Alshammari, et al.
Published: (2025-12-01) -
Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis
by: Jinqiao Li, et al.
Published: (2024-12-01)